This month we've had Eyes On The BBB and potential timing and impact on the BioPharma sector. This is a dynamic area, with many different news bytes daily, let us know what you'v e seen and what sources you are following.

We've had Eyes On the Datroway approval, and the associated removal of REMS requirements for CAR-T Therapeutics, along with a Biocon deal with Regeneron, and Bharat Biotech expansion plans for CGT manufacturing.

We've had Eyes on several firms that are actively executing on their strategic plans to ensure competitiveness in their markets. Take a look at how BioNTech, Novo Nordisk, and Merck are adapting to changing markets and technologies.

This week we've kept Eyes On the MFN and Tariff news, plus the Moderna x HHS Break-up and the Lilly x SiteOne Deal. The BioPharma Marketplace is in flux and we're watching to see how everyone is adapting and re-aligning their strategies.

We're catching up on the latest news and views surrounding the BioPharma Industry & Tariffs.

Just two weeks after our initial blogpost was published, 23andMe has made headlines again — this time for being acquired by Regeneron Pharmaceuticals in a deal valued at $256 million.